Background: Uterine leiomyomas (ULs) are the most common gynecologic tumors and affect 3 of every 4 women by the age of 50 years. The majority of ULs are classified as conventional tumors, whereas 10% represent various histopathological subtypes with features that mimic malignancy. These subtypes include cellular and mitotically active ULs and ULs with bizarre nuclei. Uterine leiomyosarcoma (ULMS), the malignant counterpart of UL, is an aggressive cancer with poor overall survival. The early diagnosis and preoperative differentiation of ULMS from UL are often challenging because their symptoms and morphology resemble one another. Recent studies have shown frequent loss of alpha-thalassemia/mental retardation syndrome X-linked (ATRX) or death domain-associated protein (DAXX) expression in ULMS, and this is often associated with an alternative lengthening of telomeres (ALT) phenotype.

Methods: To investigate ATRX and DAXX expression and the presence of ALT in UL subtypes, immunohistochemical and telomere-specific fluorescence in situ hybridization analyses were performed. The study material consisted of 142 formalin-fixed, paraffin-embedded tissue samples representing various UL subtypes and 64 conventional ULs.

Results: A loss of ATRX or DAXX and/or ALT was detected in 6.3% of the histopathological UL subtype samples (9 of 142). Two patients whose ULs showed either ATRX loss or ALT were later diagnosed with a pulmonary smooth muscle tumor. Pulmonary tumors displayed molecular alterations found in the corresponding uterine tumors, which indicated metastasis to the lungs. All conventional ULs displayed normal ATRX, DAXX, and telomeres.

Conclusions: These results highlight the differences between conventional and histopathologically atypical ULs and indicate that some UL subtype tumors may harbor long-term malignant potential.

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31754DOI Listing

Publication Analysis

Top Keywords

atrx daxx
12
alternative lengthening
8
lengthening telomeres
8
uterine leiomyomas
8
daxx expression
8
uls
7
tumors
5
atrx
5
loss
4
loss atrx/daxx
4

Similar Publications

ATRX loss inhibits DDR to strengthen radio-sensitization in p53-deficent HCT116 cells.

Sci Rep

January 2025

NHC Key Laboratory of Radiobiology (Jilin University), School of Public Health, Jilin University, Changchun, 130021, Jilin, People's Republic of China.

Identifying novel targets for molecular radiosensitization is critical for improving the efficacy of colorectal cancer (CRC) radiotherapy. Alpha-thalassemia/mental retardation X-linked (ATRX), a member of the SWI/SNF-like chromatin remodeling protein family, functions in the maintenance of genomic integrity and the regulation of apoptosis and senescence. However, whether ATRX is directly involved in the radiosensitivity of CRC remains unclear.

View Article and Find Full Text PDF
Article Synopsis
  • Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) can be either hormone-secreting or non-secreting, have serious health implications, and an average survival of 75-124 months.
  • Research shows that key genes involved in the tumor's development, especially epigenetic regulators like MEN1, DAXX, and ATRX, are often mutated, but their effects are not well understood.
  • The calcium sensing receptor (CaSR) is significantly reduced in GEP-NETs, potentially due to DNA methylation and chromatin modifications, suggesting it functions as a tumor suppressor by inhibiting cell growth in pancreatic NETs.
View Article and Find Full Text PDF

High-grade or grade 3 epithelial neuroendocrine neoplasms (G3 NEN) are now divided into grade 3 well-differentiated neuroendocrine tumor (G3 NET) and neuroendocrine carcinoma (NEC), both defined by Ki-67 > 20% and/or > 20 mitoses per 2 mm. NET and NEC are thought to be distinct tumors with different genetic profiles: NEC classically harbors co-alteration of TP53 and RB1, whereas NET genetics are site-dependent with frequent alterations in MEN1, ATRX, DAXX, and TSC1/2 in pancreatic NETs. Progression from NET to NEC is considered rare and is not well described.

View Article and Find Full Text PDF

Diagnostic and prognostic biomarkers for pancreatic neuroendocrine neoplasms.

Pathologie (Heidelb)

November 2024

Department of Pathology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

Article Synopsis
  • - The review discusses pancreatic neuroendocrine neoplasms (PanNENs), which are diverse tumors that can be classified into well-differentiated pancreatic neuroendocrine tumors (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs), using specific neuroendocrine markers for diagnosis.
  • - Diagnostic markers like chromogranin A, synaptophysin, and INSM1 help confirm neuroendocrine differentiation, with the World Health Organization classifying PanNENs based on differentiation and proliferative activity, using the Ki-67 index.
  • - Prognostic factors such as ATRX and DAXX loss indicate a higher risk of metastasis and recurrence in
View Article and Find Full Text PDF
Article Synopsis
  • Molecular studies indicate that ALT is a crucial prognostic marker for shorter relapse-free survival (RFS) in pancreatic neuroendocrine tumors (PanNETs) and other neoplasms.
  • The development of a new chromogenic ALT assay (ALT-CISH) was initiated to address clinical limitations of the traditional fluorescence in situ hybridization (FISH) method, showing a 100% agreement with FISH results in validating that ALT is present in 31% of primary PanNETs.
  • The study demonstrated that ALT status is significantly associated with poorer RFS in both PanNET and leiomyosarcoma (LMS) patients, with ALT being an independent prognostic factor
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!